At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
JNJ-73763989 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-label Trial to Evaluate Safety, Efficacy, Tolerability, and Pharmacodynamics of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs, and a PD-1 Inhibitor in Chronic Hepatitis B Patients
In Brief
A Phase 2 clinical trial evaluating JNJ-73763989, PD-1 inhibitor, and 3 other interventions for Hepatitis B, Chronic. Completed, enrolled 37 participants across 26 sites in 8 countries.
Detailed Summary
The purpose of this study is to evaluate efficacy of the study intervention, based on hepatitis B surface antigen (HBsAg) levels at follow-up (FU) Week 24.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesCanada, Czechia, France, Italy, Spain, Taiwan, Turkey (Türkiye), United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartJun 2022
Primary CompletionDec 2023
Study CompletionMay 2024
TodayJul 2026
First PostedMar 11, 2022
Enrollment StartJun 30, 2022
Primary CompletionDec 12, 2023
Study CompletionMay 31, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.3 years ago
Interventions
JNJ-73763989drug
JNJ-73763989 will be administered subcutaneously.
PD-1 inhibitordrug
PD-1 inhibitor will be administered as IV infusion.
Tenofovir Disoproxildrug
Tenofovir disoproxil film-coated tablets will be administered orally.
Tenofovir Alafenamidedrug
TAF film-coated tablets will be administered orally.
Entecavirdrug
ETV film-coated tablets will be administered orally.